Ratings by Cantor Fitzgerald (Charles Duncan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/22/2025 | Solid Biosciences | SLDB | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/21/2025 | Solid Biosciences | SLDB | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/11/2025 | Solid Biosciences | SLDB | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/17/2025 | Solid Biosciences | SLDB | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/27/2025 | Prothena Corp | PRTA | Downgrade | Neutral (Overweight) |
6.58 (9.59) |
45.74% | Details | |
| 5/13/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/3/2025 | Cytokinetics | CYTK | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/26/2025 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/14/2025 | Vanda Pharmaceuticals | VNDA | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/13/2025 | Intra-Cellular Therapies | ITCI | Downgrade | Neutral (Overweight) |
94.87 (131.87) |
39% | Details | |
| 1/10/2025 | Bright Minds Biosciences Inc. | DRUG | New Coverage | Overweight (N/A) |
41.04 (76.87) |
87.31% | Details | |
| 8/1/2024 | Vanda Pharmaceuticals | VNDA | Maintain | Overweight (N/A) |
|
Details | ||
| 7/30/2024 | Cognition Therapeutics | CGTX | Downgrade | Neutral (Overweight) |
2.37 (1.03) |
-56.54% | Details | |
| 7/11/2024 | Vanda Pharmaceuticals | VNDA | New Coverage | Overweight (N/A) |
5.21 (7.89) |
51.44% | Details | |
| 4/16/2024 | Marinus Pharmaceuticals | MRNS | Maintain | Overweight (N/A) |
|
Details | ||
| 12/7/2023 | Cerevel Therapeutics | CERE | Downgrade | Neutral (Overweight) |
35.59 (44.96) |
26.33% | Details | |
| 11/3/2023 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 10/9/2023 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 9/22/2023 | Solid Biosciences | SLDB | New Coverage | Overweight (N/A) |
2.74 (6.75) |
146.35% | Details | |
| 8/15/2023 | Lumos Pharma | LUMO | Maintain | Overweight (N/A) |
|
Details | ||
| 8/7/2023 | Vaxart Inc. | VXRT | Maintain | Overweight (N/A) |
|
Details | ||
| 8/4/2023 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 8/2/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 7/24/2023 | Reata Pharmaceuticals | RETA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2023 | Prothena Corp | PRTA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/5/2023 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 4/25/2023 | Xenon Pharmaceuticals | XENE | New Coverage | Overweight (N/A) |
39.26 (41.94) |
6.83% | Details | |
| 4/6/2023 | Fennec Pharmaceuticals Inc. | FENC | Maintain | Overweight (N/A) |
|
Details | ||
| 4/4/2023 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 4/3/2023 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 3/29/2023 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 3/28/2023 | Karuna Therapeutics Inc. | KRTX | New Coverage | Neutral (N/A) |
197.82 (329.83) |
66.73% | Details | |
| 3/27/2023 | Reata Pharmaceuticals | RETA | Maintain | Overweight (N/A) |
|
Details | ||
| 3/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 3/1/2023 | Reata Pharmaceuticals | RETA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/7/2023 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/6/2023 | atai Life Sciences N.V | ATAI | Maintain | Overweight (N/A) |
|
Details | ||
| 12/21/2022 | Prothena Corp | PRTA | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2022 | Cerevel Therapeutics | CERE | Maintain | Overweight (N/A) |
|
Details | ||
| 12/6/2022 | Anavex Life Sciences | AVXL | Downgrade | Neutral (Overweight) |
12.05 (4.65) |
-61.41% | Details | |
| 11/23/2022 | Cognition Therapeutics | CGTX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/22/2022 | Fennec Pharmaceuticals Inc. | FENC | Upgrade | Overweight (Neutral) |
8.71 (7.70) |
-11.6% | Details | |
| 11/22/2022 | Fennec Pharmaceuticals Inc. | FENC | Downgrade | Neutral (Overweight) |
8.58 (7.70) |
-10.26% | Details | |
| 11/9/2022 | Reata Pharmaceuticals | RETA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/9/2022 | Prothena Corp | PRTA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/7/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/1/2022 | Cardiol Therapeutics | CRDL | Maintain | Overweight (N/A) |
|
Details | ||
| 10/26/2022 | Biohaven Pharmaceutical Holding | BHVN | Upgrade | Overweight (Neutral) |
14.41 (9.92) |
-31.16% | Details | |
| 9/29/2022 | Cognition Therapeutics | CGTX | New Coverage | Overweight (N/A) |
1.74 (1.03) |
-40.8% | Details | |
| 9/29/2022 | Cerevel Therapeutics | CERE | New Coverage | Overweight (N/A) |
28.00 (44.96) |
60.57% | Details | |
| 5/17/2022 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 4/20/2022 | Marinus Pharmaceuticals | MRNS | Maintain | Overweight (N/A) |
|
Details | ||
| 4/8/2022 | Aptinyx | APTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2022 | Kalvista Pharmaceuticals Inc | KALV | Maintain | Overweight (N/A) |
|
Details | ||
| 3/9/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2022 | vTv Therapeutics | VTVT | New Coverage | Overweight (N/A) |
0.72 (35.41) |
4818.06% | Details | |
| 1/10/2022 | Bionomics Ltd. | BNOX | New Coverage | Overweight (N/A) |
11.55 (0.25) |
-97.84% | Details | |
| 1/4/2022 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/20/2021 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 12/17/2021 | Cardiol Therapeutics | CRDL | New Coverage | Overweight (N/A) |
1.87 (0.97) |
-48.13% | Details | |
| 11/2/2021 | Vaxart Inc. | VXRT | New Coverage | Overweight (N/A) |
6.97 (0.32) |
-95.41% | Details | |
| 9/17/2021 | Prothena Corp | PRTA | Maintain | Overweight (N/A) |
|
Details | ||
| 9/13/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 6/28/2021 | Anavex Life Sciences | AVXL | Maintain | Overweight (N/A) |
|
Details | ||
| 6/1/2021 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2021 | Clene, Inc. | CLNN | New Coverage | Overweight (N/A) |
9.00 (5.36) |
-40.44% | Details | |
| 2/23/2021 | Anavex Life Sciences | AVXL | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2020 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2020 | GW Pharma | GWPH | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 12/29/2020 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 12/28/2020 | Inovio Pharmaceuticals | INO | Maintain | Neutral (N/A) |
|
Details | ||
| 10/5/2020 | Cytokinetics | CYTK | Maintain | Overweight (N/A) |
|
Details | ||
| 9/28/2020 | Inovio Pharmaceuticals | INO | Downgrade | Hold (Buy) |
16.94 (1.74) |
-89.73% | Details | |
| 9/11/2020 | Prevail Therapeutics | PRVL | New Coverage | Overweight (N/A) |
11.11 (23.00) |
107.02% | Details | |
| 9/1/2020 | Aimmune Therapeutics | AIMT | Downgrade | Neutral (Buy) |
12.60 (34.49) |
173.73% | Details | |
| 6/1/2020 | Geron Corporation | GERN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/18/2020 | Reata Pharmaceuticals | RETA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/11/2020 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/8/2020 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2020 | Neurocrine Bio. | NBIX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/4/2020 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/27/2020 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2020 | Reata Pharmaceuticals | RETA | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2020 | Stealth BioTherapeutics | MITO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/18/2020 | Intra-Cellular Therapies | ITCI | Maintain | Overweight (N/A) |
|
Details | ||
| 2/14/2020 | Catalyst Pharmaceutical Partners | CPRX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/26/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 11/20/2019 | Halozyme Therapeutics | HALO | Maintain | Overweight (N/A) |
|
Details | ||
| 11/15/2019 | Zosano Pharma | ZSAN | Maintain | Overweight (N/A) |
|
Details | ||
| 11/4/2019 | Reata Pharmaceuticals | RETA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/28/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/15/2019 | Reata Pharmaceuticals | RETA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/1/2019 | Geron Corporation | GERN | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/27/2019 | Stealth BioTherapeutics | MITO | New Coverage | Overweight (N/A) |
5.96 (0.32) |
-94.63% | Details | |
| 9/23/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 9/9/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 8/27/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Overweight (N/A) |
|
Details | ||
| 8/15/2019 | Geron Corporation | GERN | New Coverage | Overweight (N/A) |
1.29 (1.53) |
18.6% | Details | |
| 7/17/2019 | Inovio Pharmaceuticals | INO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/26/2019 | Biohaven Pharmaceutical Holding | BHVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/30/2019 | electroCore Inc. | ECOR | Downgrade | Neutral (Overweight) |
2.06 (2.57) |
24.76% | Details | |
| 4/23/2019 | Zosano Pharma | ZSAN | New Coverage | Overweight (N/A) |
3.40 (0.56) |
-83.53% | Details | |
| 3/22/2019 | Aptinyx | APTX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2019 | Voyager Therapeutics | VYGR | New Coverage | Overweight (N/A) |
18.19 (9.03) |
-50.36% | Details | |
| 3/4/2019 | Prothena Corp | PRTA | New Coverage | Overweight (N/A) |
13.40 (9.59) |
-28.43% | Details | |
| 2/6/2019 | Vanda Pharmaceuticals | VNDA | Downgrade | Neutral (Overweight) |
25.30 (7.89) |
-68.81% | Details | |
| 2/1/2019 | Corcept Therapeutics | CORT | Downgrade | Neutral (Overweight) |
11.18 (33.87) |
202.95% | Details | |
| 12/12/2018 | Corcept Therapeutics | CORT | Upgrade | Overweight (Neutral) |
12.98 (11.18) |
-13.87% | Details | |
| 12/4/2018 | Vanda Pharmaceuticals | VNDA | Upgrade | Overweight (Neutral) |
25.04 (25.30) |
1.04% | Details | |
| 12/3/2018 | Aimmune Therapeutics | AIMT | New Coverage | Overweight (N/A) |
23.65 (34.49) |
45.84% | Details | |
| 11/5/2018 | Adverum Biotechnologies | ADVM | New Coverage | Neutral (N/A) |
4.55 (10.94) |
140.44% | Details | |
| 9/21/2018 | Zynerba Pharmaceuticals | ZYNE | New Coverage | Overweight (N/A) |
7.86 (1.30) |
-83.46% | Details | |
| 9/21/2018 | Cara Therapeutics | CARA | New Coverage | Overweight (N/A) |
22.20 (5.32) |
-76.04% | Details | |
| 9/21/2018 | Kalvista Pharmaceuticals Inc | KALV | New Coverage | Overweight (N/A) |
16.26 (16.23) |
-0.18% | Details | |
| 9/21/2018 | electroCore Inc. | ECOR | New Coverage | Overweight (N/A) |
13.93 (2.06) |
-85.21% | Details | |
| 9/21/2018 | Cytokinetics | CYTK | New Coverage | Overweight (N/A) |
8.35 (60.41) |
623.47% | Details | |
| 9/21/2018 | Catalyst Pharmaceutical Partners | CPRX | New Coverage | Overweight (N/A) |
3.07 (24.24) |
689.58% | Details | |
| 9/21/2018 | Adverum Biotechnologies | ADVM | New Coverage | Overweight (N/A) |
5.85 (4.55) |
-22.22% | Details | |
| 8/23/2018 | Reata Pharmaceuticals | RETA | New Coverage | Overweight (N/A) |
74.19 (172.36) |
132.32% | Details | |
| 8/23/2018 | Neurocrine Bio. | NBIX | New Coverage | Overweight (N/A) |
114.43 (128.13) |
11.97% | Details | |
| 8/23/2018 | Halozyme Therapeutics | HALO | New Coverage | Overweight (N/A) |
17.22 (67.37) |
291.23% | Details | |
| 8/23/2018 | Vanda Pharmaceuticals | VNDA | New Coverage | Neutral (N/A) |
21.20 (25.04) |
18.11% | Details | |
| 8/23/2018 | Deciphera | DCPH | New Coverage | Overweight (N/A) |
34.68 (25.59) |
-26.21% | Details | |
| 8/23/2018 | Alder Biopharm | ALDR | New Coverage | Neutral (N/A) |
18.70 (18.88) |
0.96% | Details | |
| 8/23/2018 | Acadia Pharmaceuticals | ACAD | New Coverage | Overweight (N/A) |
14.11 (22.16) |
57.05% | Details |
